<DOC>
	<DOCNO>NCT01860066</DOCNO>
	<brief_summary>Study show QVA149 superior standard care , fluticasone/salmeterol , patient moderate severe airflow limitation .</brief_summary>
	<brief_title>A 12 Week Study QVA149 Compared Fluticasone/Salmeterol ( Advair ) Treatment COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Age &gt; = 40 year , patient airflow limitation indicate postbronchdilation FEV1 &gt; =30 % &lt; 80 % predict normal , current exsmokers 10 pack year smoke history , patient mMRC grade 2 great prolong QTCF &gt; 450 m , paroxysmal atrial fibrillation , Type I uncontrolled Type II diabetes , history asthma , COPD diagnosis age 40 , receive treatment allow study , concomitant pulmonary disease . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>COPD</keyword>
</DOC>